trovafloxacin (Trovan)
Jump to navigation
Jump to search
Introduction
Tradename: Trovan. (trovafloxacin mesylate) Restricted use by FDA, 1999 (hospitals & nursing homes)
Indications
- acute bacterial exacerbations of chronic bronchitis
- community acquired pneumonia
- nosocomial pneumonia
- acute sinusitis
- complicated intra-abdominal infections
- gynecologic & pelvic infections
- prophylaxis of infection associated with elective colorectal surgery, vaginal & abdominal hysterectomy
- uncomplicated skin & skin structure infections
- complicated skin & skin structure infections
- uncomplicated urinary tract infection (cystitis)
- chronic bacterial prostatitis
- uncomplicated urethral gonorrhea in males & endocervical & rectal gonorrhea in females
- Cervicitis
- pelvic inflammatory disease (mild to moderate)
Dosage
Tabs: 100 & 200 mg.
IV form is L-alanyl-L-alanyl derivative alatrofloxacin.
Antimicrobial activity
- Haemophilus influenzae
- Moraxella catarrhalis
- Haemophilus parainfluenzae
- Mycoplasma pneumonia
- Legionella pneumophila
- Chlamydia pneumoniae
- Escherichia coli
- Pseudomonas aeruginosa
- Bacteroides fragilis
- Klebsiella pneumonia
- Prevotella species
- Proteus mirabilis
- Neisseria gonorrhoeae
- Chlamydia trachomatis
- Gardnerella vaginalis
Adverse effects
- not common 1-9%
- uncommon <1%
- many, including acute liver failure